What's Left Unsaid: The Cost of Staying Silent on Coverage
Pharma commercial leaders in TAs with high clinical need often tell reps to focus on efficacy and leave the coverage conversations for later. New MMIT research reveals that this approach is costing manufacturers valuable script lift. In this research paper, learn why providers are much more likely to adopt a new therapy when they understand both its clinical value and the realities of access.
Download the Report
Discover the disconnect between how frequently specialists expect reps to share access details and how often they actually do.
Learn the four negative assumptions that specialists make when coverage information is left out of the sales conversation.
Understand what specialists need to know whether a prescription Is possible, and when they are likely to look up a patient's coverage details.